{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy&page=4", "query": { "intervention": "recombinant viral vaccine therapy", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 190, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:41:10.520Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04754594", "title": "To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection", "COVID-19", "Maternal Immunization" ], "interventions": [ { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 726, "start_date": "2021-02-16", "completion_date": "2022-07-15", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04754594" }, { "nct_id": "NCT05000216", "title": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)", "Systemic Lupus Erythematosus (SLE)", "Pemphigus Vulgaris", "Multiple Sclerosis (MS)", "Systemic Sclerosis (SSc)", "Pediatric SLE", "Juvenile Idiopathic Arthritis (JIA)", "Juvenile Dermatomyositis (JDM)", "Pediatric-Onset Multiple Sclerosis (POMS)" ], "interventions": [ { "name": "Moderna mRNA-1273", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "Ad26.COV2.S", "type": "BIOLOGICAL" }, { "name": "Continue IS (MMF or MPA)", "type": "DRUG" }, { "name": "Continue IS (MTX)", "type": "DRUG" }, { "name": "Continue IS (B cell depletion therapy)", "type": "BIOLOGICAL" }, { "name": "Monovalent [B.1.351] CoV2 preS dTM-AS03", "type": "BIOLOGICAL" }, { "name": "Withhold IS (MMF or MPA)", "type": "DRUG" }, { "name": "Withhold IS (MTX)", "type": "DRUG" }, { "name": "Withhold IS (B cell depletion therapy)", "type": "DRUG" }, { "name": "Moderna mRNA-1273, Bivalent", "type": "BIOLOGICAL" }, { "name": "BNT162b2, Bivalent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 258, "start_date": "2021-08-13", "completion_date": "2024-03-28", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 29, "location_summary": "Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05000216" }, { "nct_id": "NCT04843852", "title": "TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis B", "Chronic Hepatitis B" ], "interventions": [ { "name": "Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-10-16", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04843852" }, { "nct_id": "NCT06899802", "title": "A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Encephalitis" ], "interventions": [ { "name": "MVA-BN-WEV", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 411, "start_date": "2025-03-10", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 9, "location_summary": "Sacramento, California • Lilburn, Georgia • Lenexa, Kansas + 6 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Lilburn", "state": "Georgia" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Versailles", "state": "Kentucky" }, { "city": "Kenner", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06899802" }, { "nct_id": "NCT00000631", "title": "A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIVAC-1e", "type": "BIOLOGICAL" }, { "name": "gp160 Vaccine (MicroGeneSys)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 13, "start_date": null, "completion_date": "1992-12", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000631" }, { "nct_id": "NCT05876377", "title": "Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "SARS-CoV-2", "COVID-19", "Post-Acute COVID-19 Syndrome" ], "interventions": [ { "name": "Pfizer-BioNTech COVID-19 mRNA vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 1, "start_date": "2023-10-23", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05876377" }, { "nct_id": "NCT04834869", "title": "COVID-19 Vaccines Safety Tracking (CoVaST)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adverse Reaction to Vaccine", "COVID19 Vaccine" ], "interventions": [ { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "AZD1222", "type": "BIOLOGICAL" }, { "name": "CoronaVac", "type": "BIOLOGICAL" }, { "name": "Sinopharm", "type": "BIOLOGICAL" }, { "name": "Gam-COVID-Vac", "type": "BIOLOGICAL" }, { "name": "JNJ-78436735", "type": "BIOLOGICAL" }, { "name": "CVnCoV", "type": "BIOLOGICAL" }, { "name": "NVX-CoV2373", "type": "BIOLOGICAL" }, { "name": "BBV152", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masaryk University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30000, "start_date": "2021-04-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04834869" }, { "nct_id": "NCT00000683", "title": "A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIVAC-1e", "type": "BIOLOGICAL" }, { "name": "gp160 Vaccine (MicroGeneSys)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 54, "start_date": null, "completion_date": "1993-06", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000683" }, { "nct_id": "NCT04811664", "title": "A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection" ], "interventions": [ { "name": "Moderna COVID-19 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "18 Years to 29 Years" }, "enrollment_count": 1923, "start_date": "2021-03-24", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2023-08-02", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04811664" }, { "nct_id": "NCT00505063", "title": "Prospective Trial of Vaccine Responses in Childhood Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Cancer", "Multiple Diseases" ], "interventions": [ { "name": "Immunization Schedule patients <7 years.", "type": "BIOLOGICAL" }, { "name": "Immunization Schedule patients > or = to 7 years and <11 years of age", "type": "BIOLOGICAL" }, { "name": "Immunization Schedule patients > or = to 11 years of age", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 75, "start_date": "2007-07-10", "completion_date": "2025-06-11", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-14T11:41:10.520Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00505063" } ] }